Industry News
Pharmaceutical Industry News
Aurobindo will shell out $250…
Aurobindo will shell out $250 million to acquire drugmaker Lannett, shoring up the Indian drugmaker’s footprint in the U.S. amid threats that the Trump administration plans to impose tariffs on foreign-made drugs.
Vor Bio has handed Dallan Murray a…
Vor Bio has handed Dallan Murray a swift return to the workforce. Weeks after being let go by Sarepta Therapeutics, Murray has landed the chief commercial officer post in Vor Bio’s new-look C-suite.
Garonit Pharmaceutical, an…
Garonit Pharmaceutical, an India-based API maker, plans to build a $46.1 million production plant in New York to produce chlorhexidine gluconate, which is primarily used as an antiseptic and surgical disinfectant.
Impulsó el derecho a una muerte digna, empezando por la suya
Tatiana Andia sabía que Colombia le permitiría acceder a una muerte médicamente asistida. El trayecto hacia el final lo hizo ante los ojos de su país.
Merck pulled off its $10 billion…
Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically accompanies a big-money acquisition in the biopharma industry.
With more than $1 billion in debt…
With more than $1 billion in debt due in 2027, Sarepta said it’s “evaluating opportunities to enhance operational efficiency and adjust manufacturing commitments based on latest demand.”
Klick Media’s President shares…
Klick Media’s President shares his perspective on how AI is redefining planning, analytics and micro-segmentation in HCP marketing
Werewolf Therapeutics is…
Werewolf Therapeutics is transforming its brand awareness and clinical trial recruitment efforts with a new campaign.
The FDA approved Jazz’s Modeyso…
The FDA approved Jazz's Modeyso (dordaviprone), which was picked up in the company's $935 million buyout of Chimerix earlier this year, as the first systemic therapy for a rare type of brain cancer.
Pfizer CentreOne—the pharma…
Pfizer CentreOne—the pharma giant's integrated CMO outfit—is leveraging lessons learned from the COVID pandemic as it works to redefine the nature of the developer-manufacturer relationship.
Before a single panel kicks off,…
Before a single panel kicks off, Fierce Pharma Week already feels different.
Novo Nordisk veteran Maziar Mike…
Novo Nordisk veteran Maziar Mike Doustdar—who is set to assume the role of CEO on Thursday—will have his work cut out turning things around at the Danish drugmaker. On the one hand, the company is
Two years into CEO Bill Anderson’s…
Two years into CEO Bill Anderson's tenure, Bayer has reduced its headcount by more than 12,000, with little slowdown in the pace of dismissals. In reporting its second-quarter results, Bayer revealed that it has slashed
After beating AstraZeneca’s…
After beating AstraZeneca’s Calquence in quarterly revenue for the first time at the end of 2024, BeOne Medicines’ Brukinsa has pulled further ahead.
Supreme Group said the deal…
Supreme Group said the deal deepens its expertise in rare disease and pharma and expands the creative and omnichannel solutions it can deliver.
Raising awareness of medical…
Raising awareness of medical products and services is a marathon, not a sprint, and Babson Diagnostics has therefore selected a star with plenty of stamina for a long-term partnership.
President Donald Trump has doubled…
President Donald Trump has doubled down on his plan to assess tariffs on imported pharmaceutical products, saying they will eventually reach 250%. The new figure comes a month after Trump reiterated his plan to tax
What Is Cardiac Amyloidosis?
A quiet revolution in care is helping patients with cardiac amyloidosis, a form of heart failure that long stumped doctors.
As investors and industry watchers…
As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing reform under the Trump administration, Pfizer CEO Albert Bourla, Ph.D.—who has frequently touted his strong relationship with the
In July, spending on TV ads for…
In July, spending on TV ads for prescription drugs reached a low not seen since this time last year.